Skip to main content
. 2012 Jun 19;53(6):377–385. doi: 10.4111/kju.2012.53.6.377

TABLE 2.

Safety of daily phosphodiesterase type 5 inhibitors

graphic file with name kju-53-377-i002.jpg

BPH, benign prostatic hyperplasia.